Analyst: Buy This Small-Cap Pharma Stock

Options players are closing out their bearish positions as a result

by Lillian Currens

    Published on Mar 14, 2019 at 12:09 PM

    Jefferies just initiated coverage of Kala Pharmaceuticals Inc (NASDAQ:KALA) with a "buy" rating and a $15 price target. In response, the shares of KALA are up 1% at $8.13, trying to battle back after an ugly 2018.

    KALA stock is coming off it's Dec. 24 all-time-low of $4.03 -- now up 66.4% year-to-date. The 30-day moving average, which has pushed the stock lower in the past, has proved a recent layer of support. Plus, the equity has been testing the $9 level of late -- an area it hasn't broken north of since mid-October. 

    KALA Chart March 14

    Jefferies is joining an enthusiastic bunch. The drug concern currently boasts five "strong buy" ratings from analysts. What's more, the lofty consensus 12-month target price of $22 holds a 170.4% premium to current levels. 

    Meanwhile, some unusual put activity is taking place, with 905 contracts across the tape -- roughly six times the average intraday volume. This activity is being driven by heavy trading at the April 2.50 and 5 puts. Data shows possible spread activity at these contracts earlier in the week, and traders may now be closing out their positions. 

    Short sellers could be hitting the exits soon, too. Short interest shot up 40.4% in the last reporting period. The 1.4 million shares sold short represent a healthy 7% of the stock's available float. At KALA's average daily trading volume, it would take almost five days to buy back these bearish bets.


    a schaeffer's exclusive

    5 HOT STOCK PICKS

    Heat up your summer trading with this FREE insider report!


     
     

    Partnercenter


    NEW! Explore Schaeffer’s Partners' deals and get connected to top online brokerages with deals tailored exclusively for our readers.  Get answers to your questions regarding transfer fees, commission rates, programs and available discounts related to online trading services.

    MORE | MARKETstories


    This Might Be the Ultimate Cannabis Stock
    This innovative company could help investors see some major upside.
    3 Drug Stocks Seeing Unusual Options Trading Today
    The FDA approved Sesen's request to move manufacturing for its bladder cancer drug
    BofA-Merrill Lynch: Buy This Shoe Stock Before Earnings
    The brokerage firm thinks the retailer can rally another 26%
    This Might Be the Ultimate Cannabis Stock
    This innovative company could help investors see some major upside.